These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 33371161

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology.
    Cheng Y, Chen ZY, Huang JJ, Shao D.
    Eur Radiol; 2023 Oct; 33(10):6625-6635. PubMed ID: 37515634
    [Abstract] [Full Text] [Related]

  • 43. Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy.
    Fledelius J, Khalil A, Hjorthaug K, Frøkiær J.
    EJNMMI Res; 2016 Dec; 6(1):71. PubMed ID: 27655428
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab.
    Chen A, Mokrane FZ, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Dulery R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Armand P, Houot R, Dercle L.
    J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
    [Abstract] [Full Text] [Related]

  • 46. The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Vekens K, Everaert H, Neyns B, Ilsen B, Decoster L.
    Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
    [Abstract] [Full Text] [Related]

  • 47. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST.
    Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M.
    EJNMMI Res; 2019 Jan 29; 9(1):8. PubMed ID: 30694399
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The early prediction of pathological response to neoadjuvant chemotherapy and prognosis: comparison of PET Response Criteria in Solid Tumors and European Organization for Research and Treatment of Cancer criteria in breast cancer.
    Lian W, Liu C, Gu B, Zhang J, Lu L, Pan H, Yao Z, Wang M, Song S, Zhang Y, Yang Z.
    Nucl Med Commun; 2020 Mar 29; 41(3):280-287. PubMed ID: 32032193
    [Abstract] [Full Text] [Related]

  • 53. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PET.
    Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M.
    Theranostics; 2020 Mar 29; 10(2):925-937. PubMed ID: 31903160
    [Abstract] [Full Text] [Related]

  • 54. Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors.
    Annovazzi A, Ferraresi V, Rea S, Russillo M, Renna D, Carpano S, Sciuto R.
    Eur Radiol; 2022 May 29; 32(5):3398-3407. PubMed ID: 34779873
    [Abstract] [Full Text] [Related]

  • 55. Early assessment of tumor response using 18F-FDG PET/CT after one cycle of systemic therapy in patients with recurrent and metastatic breast cancer.
    Kitajima K, Higuchi T, Yamakado K, Miyoshi Y.
    Hell J Nucl Med; 2022 May 29; 25(2):155-162. PubMed ID: 35913863
    [Abstract] [Full Text] [Related]

  • 56. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
    Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, Guminski AD, Long GV, Menzies AM.
    Ann Oncol; 2018 Oct 01; 29(10):2115-2120. PubMed ID: 30137228
    [Abstract] [Full Text] [Related]

  • 57. Organ-specific accuracy of [18F]FDG-PET/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor.
    Gideonse BM, Birkeland M, Vilstrup MH, Grupe P, Naghavi-Behzad M, Ruhlmann CH, Gerke O, Hildebrandt MG.
    Jpn J Radiol; 2024 Jul 01; 42(7):753-764. PubMed ID: 38504000
    [Abstract] [Full Text] [Related]

  • 58. 18F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods.
    Fledelius J, Winther-Larsen A, Khalil AA, Bylov CM, Hjorthaug K, Bertelsen A, Frøkiær J, Meldgaard P.
    J Nucl Med; 2017 Dec 01; 58(12):1931-1937. PubMed ID: 28490472
    [Abstract] [Full Text] [Related]

  • 59. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A.
    Eur Urol Focus; 2021 Sep 01; 7(5):1092-1099. PubMed ID: 33172772
    [Abstract] [Full Text] [Related]

  • 60. Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer.
    Aide N, Fauchille P, Coquan E, Ferron G, Combe P, Meunier J, Alexandre J, Berton D, Leary A, De Rauglaudre G, Bonichon N, Pujade Lauraine E, Joly F.
    Eur J Nucl Med Mol Imaging; 2021 Jun 01; 48(6):1998-2008. PubMed ID: 33221969
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.